Asset
ETBX-011
Revenue
No revenue reported in loaded filings.
Clinical trials (17)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03563157 | phase1_2 | terminated | 2018-09-28 | 2019-04-21 | ImmunityBio, Inc. | QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine |
| NCT03574649 | phase2 | withdrawn | 2018-06-01 | 2018-08-01 | ImmunityBio, Inc. | QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer |
| NCT03136406 | phase1_2 | terminated | 2017-08-11 | 2017-11-22 | ImmunityBio, Inc. | QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy |
| NCT03169738 | phase1_2 | withdrawn | 2018-02-01 | 2019-01-01 | ImmunityBio, Inc. | QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors |
| NCT03167177 | phase1_2 | withdrawn | 2017-12-01 | 2019-01-01 | ImmunityBio, Inc. | QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy |
FDA applications (0)
This company has no applications containing this asset.